Emicizumab for the treatment of haemophilia A: a narrative review

被引：43
作者：
Franchini, Massimo [1 ,2 ]
Marano, Giuseppe [2 ]
Pati, Ilaria [2 ]
Candura, Fabio [2 ]
Profili, Samantha [2 ]
Veropalumbo, Eva [2 ]
Masiello, Francesca [2 ]
Catalano, Liviana [2 ]
Piccinini, Vanessa [2 ]
Vaglio, Stefania [2 ]
Pupella, Simonetta [2 ]
Liumbruno, Giancarlo M. [2 ]
机构：
[1] Carlo Poma Hosp, Dept Haematol & Transfus Med, Str Lago Paiolo 10, I-46100 Mantua, Italy
[2] Natl Inst Hlth, Italian Natl Blood Ctr, Rome, Italy
来源：
BLOOD TRANSFUSION | 2019年 / 17卷 / 03期
关键词：
emicizumab; haemophilia A; inhibitors; bleeding; BISPECIFIC ANTIBODY; FACTOR-VIII; PHARMACOLOGICAL THERAPIES; BLEEDING EPISODES; PROPHYLAXIS; ACE910; RECOMMENDATIONS; DIAGNOSIS; FUTURE; MODEL;
D O I：
10.2450/2019.0026-19
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
One of the most serious complications of the treatment of severe haemophilia A is the development of alloantibodies against exogenous factor VIII ( FVIII). Inhibitors render factor replacement therapy ineffective, exposing patients to a remarkably high risk of morbidity and mortality. Besides the well-known bypassing agents ( i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in newer haemostatic therapies that are not based on the replacement of the deficient FVIII. This review will focus on the most interesting among these innovative therapies, emicizumab, and will provide an update on its current stage of clinical development.
引用
收藏
页码：223 / 228
页数：6
相关论文
共 46 条
[1]   Recommendations for factor VIII product source to treat patients with haemophilia A [J].
Arcieri, Romano ;
Calizzani, Gabriele ;
Candura, Fabio ;
Mannucci, Pier Mannuccio .
BLOOD TRANSFUSION, 2017, 15 (03) :285-285
[2]   Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management [J].
Benson, Gary ;
Auerswald, Guenter ;
Dolan, Gerry ;
Duffy, Anne ;
Hermans, Cedric ;
Ljung, Rolf ;
Morfini, Massimo ;
Salek, Silva Zupancic .
BLOOD TRANSFUSION, 2018, 16 (06) :535-544
[3]   Emicizumab: Review of the literature and critical appraisal [J].
Carlos Rodriguez-Merchan, E. ;
Valentino, Leonard A. .
HAEMOPHILIA, 2019, 25 (01) :11-20
[4]   The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors [J].
Castaman, Giancarlo .
BLOOD TRANSFUSION, 2017, 15 (05) :478-486
[5]   Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee [J].
Collins, P. W. ;
Liesner, R. ;
Makris, M. ;
Talks, K. ;
Chowdary, P. ;
Chalmers, E. ;
Hall, G. ;
Riddell, A. ;
Percy, C. L. ;
Hay, C. R. ;
Hart, D. P. .
HAEMOPHILIA, 2018, 24 (03) :344-347
[6]   The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A [J].
Coppola, Antonio ;
Santagostino, Elena ;
Hassan, Hamisa J. ;
Molinari, Angelo C. ;
Santoro, Rita C. ;
Tagliaferri, Annarita ;
Morfini, Massimo ;
Di Minno, Giovanni .
BLOOD TRANSFUSION, 2017, 15 (03) :281-282
[7]   Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia [J].
Farrugia, Albert ;
Liumbruno, Giancarlo M. ;
Candura, Fabio ;
Profili, Samantha ;
Cassar, Josephine .
BLOOD TRANSFUSION, 2018, 16 (06) :525-534
[8]   Non-factor replacement therapy for haemophilia: a current update [J].
Franchini, Massimo ;
Mannucci, Pier Mannuccio .
BLOOD TRANSFUSION, 2018, 16 (05) :457-461
[9]   Hemophilia A in the third millennium [J].
Franchini, Massimo ;
Mannucci, Pier Mannuccio .
BLOOD REVIEWS, 2013, 27 (04) :179-184
[10]   The modern treatment of haemophilia: a narrative review [J].
Franchini, Massimo .
BLOOD TRANSFUSION, 2013, 11 (02) :178-182
12345